Dimerization of β-tryptase inhibitors, does it work for both basic and neutral P1 groups?

Area of Science:

• Biochemistry and enzymology
• Drug discovery and medicinal chemistry

Background:

• Beta-tryptase possesses a tetrameric structure with pairwise substrate binding sites.
• This unique architecture presents an opportunity for designing inhibitors that target adjacent binding sites.
• Previous success involved dimeric inhibitors with basic P1 moieties exhibiting tight-binding properties.

Purpose of the Study:

• To design and synthesize dimeric inhibitors with neutral P1 groups.
• To leverage the dimeric binding mode for beta-tryptase inhibitor optimization.
• To investigate the feasibility of developing neutral-P1 inhibitors for beta-tryptase.

Main Methods:

• Structure-based inhibitor design targeting beta-tryptase.
• Synthesis of novel dimeric compounds with neutral P1 moieties.
• Evaluation of inhibitor binding characteristics and efficacy.

Main Results:

• The attempt to create dimeric inhibitors with neutral P1 groups was unsuccessful.
• The study identified a crucial role for Alanine 190 (Ala190) in the binding of neutral P1 groups.
• These findings cast doubt on the viability of developing neutral-P1 inhibitors for beta-tryptase using this strategy.

Conclusions:

• The dimeric binding mode is less effective for neutral P1 inhibitors compared to basic P1 inhibitors.
• Alanine 190 is a key residue influencing the binding of neutral P1 moieties in beta-tryptase.
• Further research is needed to explore alternative strategies for developing neutral-P1 beta-tryptase inhibitors.